22q11.2 Deletion Syndrome (DiGeorge): Its impact on families and why early detection matters

Genetic Counselor Awareness Day 2024

Introduction to Genetic Counseling Roles in Industry

Importance of high detection 22q screening

Dr. Sam Leonard, Sr. Medical Director (Natera), walks through how to appropriately consider the balance between high detection rates and screen positive rates when selecting a screen.

Importance of 22q screening and KOL testimonial

Dr. Blagowidow, OB Geneticist, talks about the importance of early prenatal 22q11.2 deletion syndrome (22q, formerly DiGeorge syndrome) screening and factors to consider when selecting a screen.

Fetal RhD NIPT: do all Rh negative patients need Rh immune globulin?

The evolution of NIPT: what comes next

In this talk, we will highlight how early, highly accurate prenatal screening optimizes outcomes for patients with 22q11.2 deletion syndrome, and review recently-published data from a large clinical v

Clinical Validation of a SNP-based Prenatal Cell-free DNA Screening Test for Fetal RHD Status in a Large US Cohort

Fetal RhD NIPT: A new testing option to inform care for RhD alloimmunized patients and those at risk

Natera™'s Fetal RhD NIPT (noninvasive prenatal testing) is now available. The test is backed by the largest clinical validation study for fetal RhD in the US to date, and demonstrated 100 percent sens

It's time to screen routinely for 22q11.2 deletion syndrome: new evidence of improved outcomes with prenatal diagnosis

To manage pregnancies at high risk for 22q11.2 deletion syndrome (DS), prenatal and neonatal evaluation after high risk cfDNA screening is needed. Supplemental assessments and early intervention can i

Carrier Manifestations in Pregnancy

Utility of carrier screening to inform management